MORRIS PLAINS, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Rob Iannone, M.D., has decided to leave the Company to pursue a career opportunity close to his home in Pennsylvania.
“I am proud to have been part of Immunomedics and have full confidence in the capabilities of the team to bring sacituzumab govitecan to patients in a timely manner and help patients with difficult-to-treat cancers across the U.S. and the world. My decision comes after careful consideration and is driven by my personal priorities and a desire to be close to my family after many years of having worked far away from home,” commented Dr. Rob Iannone.
Behzad Aghazadeh, Executive Chairman of Immunomedics, commented, “We thank Rob for his service to the Company, and wish him well in his new endeavors. Over the past year, Rob has played a key role in establishing and executing Immunomedics’ clinical development and regulatory strategy. Rob has built a strong R&D organization with deep clinical experience in oncology drug development and managing global clinical trials. Over the coming period, Rob will work closely with Company management and his leadership team to ensure a smooth transition, and possibly provide additional counsel in the period thereafter. Rob will also continue to work with our new partners at Everest Medicines to ensure a robust launch of the partnership between our two development organizations.”
The Company has commenced a search for a replacement and also has identified consultants who will provide support during the interim period.
About Immunomedics
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at https://immunomedics.com/.
